يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Banerjee, Susana"', وقت الاستعلام: 1.51s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

    المؤلفون: Banerjee, Susana1 (AUTHOR) susana.banerjee@rmh.nhs.uk, Moore, Kathleen N2 (AUTHOR), Colombo, Nicoletta3 (AUTHOR), Scambia, Giovanni4 (AUTHOR), Kim, Byoung-Gie5 (AUTHOR), Oaknin, Ana6 (AUTHOR), Friedlander, Michael7 (AUTHOR), Lisyanskaya, Alla8 (AUTHOR), Floquet, Anne9 (AUTHOR), Leary, Alexandra10 (AUTHOR), Sonke, Gabe S11 (AUTHOR), Gourley, Charlie12 (AUTHOR), Oza, Amit13 (AUTHOR), González-Martín, Antonio14 (AUTHOR), Aghajanian, Carol15 (AUTHOR), Bradley, William H16 (AUTHOR), Holmes, Eileen17 (AUTHOR), Lowe, Elizabeth S18 (AUTHOR), DiSilvestro, Paul19 (AUTHOR)

    المصدر: Lancet Oncology. Dec2021, Vol. 22 Issue 12, p1721-1731. 11p.

    مصطلحات موضوعية: *OVARIAN cancer, *DIAGNOSIS, *OLAPARIB, *BRCA genes, *SURVIVAL rate, *ACUTE myeloid leukemia, *PROTEINS, *RESEARCH, *OVARIAN tumors, *GENETIC mutation, *HETEROCYCLIC compounds, *RESEARCH methodology, *PROGNOSIS, *MEDICAL cooperation, *EVALUATION research, *COMPARATIVE studies, *DRUG therapy, *ENDOMETRIAL tumors, *BLIND experiment, *TUMORS, *LONGITUDINAL method

    الشركة/الكيان: MERCK KGaA , ASTRAZENECA PLC AZN


    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.

    المؤلفون: Friedlander, Michael1 Michael.Friedlander@health.nsw.gov.au, Banerjee, Susana2, Mileshkin, Linda3, Scott, Clare4, Shannon, Catherine5, Goh, Jeffrey6

    المصدر: Asia Pacific Journal of Clinical Oncology. Dec2016, Vol. 12 Issue 4, p323-331. 9p.

    مصطلحات موضوعية: *POLYMERASES, *ENZYME inhibitors, *DRUG toxicity, *OVARIAN cancer treatment, *BRCA genes, *GENETIC mutation


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.

    المؤلفون: Colombo, Nicoletta1 (AUTHOR) nicoletta.colombo@ieo.it, Moore, Kathleen2 (AUTHOR), Scambia, Giovanni3 (AUTHOR), Oaknin, Ana4 (AUTHOR), Friedlander, Michael5 (AUTHOR), Lisyanskaya, Alla6 (AUTHOR), Floquet, Anne7,8 (AUTHOR), Leary, Alexandra8,9 (AUTHOR), Sonke, Gabe S.10 (AUTHOR), Gourley, Charlie11 (AUTHOR), Banerjee, Susana12 (AUTHOR), Oza, Amit13 (AUTHOR), González-Martín, Antonio14 (AUTHOR), Aghajanian, Carol15 (AUTHOR), Bradley, William H.16 (AUTHOR), Kim, Jae-Weon17 (AUTHOR), Mathews, Cara18 (AUTHOR), Liu, Joyce19 (AUTHOR), Lowe, Elizabeth S.20 (AUTHOR), Bloomfield, Ralph21 (AUTHOR)

    المصدر: Gynecologic Oncology. Oct2021, Vol. 163 Issue 1, p41-49. 9p.

    مصطلحات موضوعية: *OVARIAN cancer, *OLAPARIB, *BRCA genes, *DIAGNOSIS, *PROGRESSION-free survival, *NEUTROPENIA


    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

    المؤلفون: Friedlander, Michael1 (AUTHOR) m.friedlander@unsw.edu.au, Moore, Kathleen N2 (AUTHOR), Colombo, Nicoletta3,4 (AUTHOR), Scambia, Giovanni5 (AUTHOR), Kim, Byoung-Gie6 (AUTHOR), Oaknin, Ana7 (AUTHOR), Lisyanskaya, Alla8 (AUTHOR), Sonke, Gabe S9 (AUTHOR), Gourley, Charlie10 (AUTHOR), Banerjee, Susana11,12 (AUTHOR), Oza, Amit13 (AUTHOR), González-Martín, Antonio14 (AUTHOR), Aghajanian, Carol15 (AUTHOR), Bradley, William H16 (AUTHOR), Liu, Joyce17 (AUTHOR), Mathews, Cara18 (AUTHOR), Selle, Frédéric19,20 (AUTHOR), Lortholary, Alain20,21 (AUTHOR), Lowe, Elizabeth S22 (AUTHOR), Hettle, Robert23 (AUTHOR)

    المصدر: Lancet Oncology. May2021, Vol. 22 Issue 5, p632-642. 11p.

    مصطلحات موضوعية: *OVARIAN cancer, *INTERACTIVE voice response (Telecommunication), *DISEASE progression, *BRCA genes, *PLACEBOS, *PROGRESSION-free survival, *OLAPARIB, *RESEARCH, *GENETIC mutation, *OVARIAN tumors, *HETEROCYCLIC compounds, *RESEARCH methodology, *HEALTH outcome assessment, *HEALTH status indicators, *MEDICAL cooperation, *EVALUATION research, *COMPARATIVE studies, *RANDOMIZED controlled trials, *QUALITY of life, *BLIND experiment, *QUESTIONNAIRES

    الشركة/الكيان: ASTRAZENECA PLC AZN, MERCK & Co. Inc. 001317064 MRK


    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1.

    المؤلفون: Bradley, William1 (AUTHOR), Moore, Kathleen2 (AUTHOR), Colombo, Nicoletta3 (AUTHOR), Scambia, Giovanni4 (AUTHOR), Kim, Byoung-Gie5 (AUTHOR), Oaknin, Ana6 (AUTHOR), Friedlander, Michael7 (AUTHOR), Lisyanskaya, Alla8 (AUTHOR), Floquet, Anne9 (AUTHOR), Leary, Alexandra10 (AUTHOR), Sonke, Gabe11 (AUTHOR), Gourley, Charlie12 (AUTHOR), Banerjee, Susana13 (AUTHOR), Oza, Amit14 (AUTHOR), González-Martín, Antonio15 (AUTHOR), Aghajanian, Carol16 (AUTHOR), Cain, Theresa17 (AUTHOR), Lowe, Elizabeth17 (AUTHOR), DiSilvestro, Paul18 (AUTHOR)

    المصدر: Gynecologic Oncology. 2021 Supplement 1, Vol. 162, pS25-S26. 2p.

    مصطلحات موضوعية: *OVARIAN cancer, *DIAGNOSIS, *OLAPARIB, *BRCA genes, *ACUTE myeloid leukemia, *PROGRESSION-free survival


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث